Clinical trials: Hyperparathyroidism
Kidney Disease, Secondary Hyperparathyroidism
START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism
The purpose of this research is to study the effects and safety of Sensipar approved by the Food and Drug Administration (FDA) in patients with kidney failure who are being treated with dialysis and have uncontrolled secondary…
- Conditions
- Kidney Disease, Secondary Hyperparathyroidism, Chronic Kidney Disease
- Trial name
- NCT00132431
- Testing
- Sensipar
- Volunteers
- 300 people
- Sponsor
- Amgen
Osteoporosis, Secondary Hyperparathyroidism
Calcium and Vitamin D Malnutrition in Elderly Women
This study is designed to test whether calcium supplementation alone or calcium plus vitamin D reduces the incidence of fractures, reduces high parathyroid secretory activity, and halts bone loss in a population-based sample of…
- Trial name
- NCT00352170
- Testing
- calcium supplementation, calcium and vitamin D3 supplementation
- Volunteers
- 1,180 people, healthy volunteers welcome
- Sponsor
- Creighton University
Hyperparathyroidism
Interaction Between Anaesthetics and Methylene Blue
We hypothesized that pre-treatment with methylene blue could potentiate the effects of general anaesthetic agents in patients undergoing parathyroidectomy
- Trial name
- NCT00513032
- Testing
- methylene blue
- Where
- Switzerland
- Volunteers
- 22 people
- Sponsor
- University Hospital, Geneva
Secondary Hyperparathyroidism
IOPTH Usefulness for Predicting Successful Surgery in Secondary Hyperparathyroidism
Secondary hyperparathyroidism (SHPT) is a multisystemic syndrome that affects calcium and bone homeostasis in patients with chronic kidney disease (CKD).
- Trial name
- NCT04484116
- Testing
- Intraoperative Paratohormone
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Hospital General Ajusco Medio
Renal Osteodystrophy
Low Magnitude Mechanical Stimuli Effects on Bone Structure in ESRD
The proposed 6 month pilot and feasibility randomized trial will evaluate LMMS as an anabolic stimulus to bone in 30 adults on maintenance hemodialysis.
- Trial name
- NCT00364234
- Testing
- Low magnitude mechanical stimuli
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Secondary Hyperparathyroidism, Hemodialysis
Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism
This study is a exploratory comparison of the efficacy and safety of paricalcitol injection with maxacalcitol injection in chronic kidney disease participants receiving hemodialysis with secondary hyperparathyroidism.
- Trial name
- NCT00990704
- Testing
- paricalcitol, maxacalcitol
- Where
- 14 sites in Japan
- Volunteers
- 47 people
- Sponsor
- Abbott
Primary Hyperparathyroidism, Bone Diseases, Metabolic
Radius Loading in Primary Hyperparathyroidism
The purpose of the study is to determine the effect of forearm exercise on forearm bone density in post-menopausal women with or without primary hyperparathyroidism.
- Conditions
- Primary Hyperparathyroidism, Bone Diseases, Metabolic, Osteoporosis, Postmenopausal, Bone Loss, Postmenopausal
- Trial name
- NCT01571843
- Testing
- Forearm exercise program, Walking program
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Columbia University
Hyperparathyroidism
The Effects of Alendronate After Cure of Primary Hyperparathyroidism
We are investigating whether, after surgical cure of primary hyperparathyroidism, alendronate provides even greater beneficial skeletal effects than parathyroidectomy alone.
- Trial name
- AlenPostPara (NCT00359385)
- Testing
- Alendronate 70mg weekly
- Where
- United States
- Sponsor
- Columbia University
Secondary Hyperparathyroidism, Hemodialysis
Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism
This study is a comparison of the efficacy and safety of paricalcitol injection with maxacalcitol injection in adult Japanese chronic kidney disease patients receiving hemodialysis with secondary hyperparathyroidism.
- Trial name
- NCT01341782
- Testing
- paricalcitol, maxacalcitol
- Where
- 45 sites in Japan
- Volunteers
- 255 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hyperparathyroidism, Primary, Parathyroid Neoplasms
WHITE CAP: Intra-operative Parathyroid Tissue Sensor (PTS)-Guided Assessment of Parathyroid Viability and Surgical Decision-Making
Primary hyperparathyroidism is usually cured by removing the single over-active parathyroid adenoma. During surgery, however, surgeons often see a thin rim of normal parathyroid tissue that still "glows" under a near-infrared…
- Conditions
- Hyperparathyroidism, Primary, Parathyroid Neoplasms, Parathyroid Adenoma, Hypocalcemia
- Trial name
- WHITE CAP-PTS (NCT07043010)
- Testing
- Near-Infrared Parathyroid Tissue Sensor Imaging (PTS), Rim-Preservation Technique, En-bloc Resection Technique
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fujian Medical University
Chronic Kidney Diseases, Hypertension
Integrated Diagnosis and Treatment of CKD on Outcomes
Objective: To establish a study cohort and follow up of patients with CKD in our hospital, and evaluate the status of integrated CKD diagnosis and treatment according to guidelines in the real world, as well as the clinical…
- Conditions
- Chronic Kidney Diseases, Hypertension, Hyperglycemia, Hyperlipidemias
- Trial name
- NCT05242055
- Testing
- Integrated diagnosis and treatment for CKD
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Capital Medical University
Primary Hyperparathyroidism
Effect of Parathyroidectomy on Cardiovascular Health
The aim of this study is to establish whether patients with mild primary hyperparathyroidism (PHPT) have an increased risk of cardiovascular diseases.
- Trial name
- NCT02989428
- Testing
- Early parathyroidectomy group (EPTX-group)
- Where
- Denmark
- Volunteers
- 69 people
- Sponsor
- University of Aarhus
Hypophosphatemic Rickets, X-Linked Dominant
Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets
This study will measure the effect of cinacalcet (Sensipar) on parathyroid hormone (PTH) secretion in children and adolescents with hypophosphatemic rickets (XLH).
- Trial name
- NCT00195936
- Testing
- Cinacalcet
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Children's Mercy Hospital Kansas City
Secondary Hyperparathyroidism, Dialysis
Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis
Prospective, non-randomized, multi-center study to assess the efficacy and safety of paricalcitol injection or oral administered over 6 months to patients with secondary hyperparathyroidism on dialysis.
- Trial name
- NCT00537979
- Testing
- Paricalcitol injection, Paricalcitol capsules
- Where
- 12 sites in Mexico
- Volunteers
- 147 people
- Sponsor
- Abbott
Hyperparathyroidism, Secondary, Hyperparathyroidism, Primary
Study on the Use of Cinacalcet in Phosphocalcic Context.
Currently, the indications used for MA (Marketing Authorization) Cinacalcet in France are hyperparathyroidism (hyperPTH) in adults, whether primary (for patients in whom parathyroidectomy is theoretically indicated but in whom it…
- Trial name
- CALCI-CINA (NCT04126954)
- Testing
- Serum PTH concentrations results
- Where
- 10 sites in France
- Volunteers
- 25 people
- Sponsor
- Hospices Civils de Lyon
Hyperparathyroidism; Secondary, Renal
Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT
1. To evaluate achievement ratio of iPTH,Calcium and phosphorus after taking Cinacalcet HCL in hemodialysis subjects with mild, moderate and severe SHPT; 2.
- Trial name
- ACTIVE (NCT03123406)
- Testing
- Cinacalcet HCl
- Where
- China
- Volunteers
- 750 people
- Sponsor
- Kyowa Kirin China Pharmaceutical Co., Ltd.
Cardiovascular Disease, Chronic Kidney Disease
Vascular Risk After Kidney Transplantation
Hypothesis: Nontraditional risk factors, such as inflammation, vitamin D deficiency, elevated PTH, insulin resistance, homocysteine, or uric acid, contribute to cardiovascular disease progression after kidney transplant.
- Conditions
- Cardiovascular Disease, Chronic Kidney Disease, Diabetes, Vitamin D Deficiency
- Trial name
- NCT00374595
- Where
- United States
- Volunteers
- 338 people
- Sponsor
- University of Nebraska
Osteoporosis, Bone Loss
Bone Microarchitectural Database Constitution From HR-pQCT Device in Clinical Situation Potentially Associated With Bone Loss
Bone fracture occurrence is associated with an increasing of morbidity and mortality. Some factors of fracture occurrence have been highlighted.
- Trial name
- DMPOs (NCT02532439)
- Testing
- HR-pQCT, DEXA, pQCT
- Where
- France
- Volunteers
- 287 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Medullary Thyroid Carcinoma, Hyperparathyroidism
PET-TC in Thyroid Evaluation
The thyroid gland may have a diffuse or focal uptake of numerous PET/CT radiopharmaceuticals and this may be correlated with underlying benign and malignant thyroid/parathyroid pathologies.
- Conditions
- Medullary Thyroid Carcinoma, Hyperparathyroidism, Parathyroid Carcinoma
- Trial name
- PEPATI-MN-2024 (NCT06852144)
- Testing
- clinical practice drug treatment
- Where
- Italy
- Volunteers
- 418 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hyperphosphatemia
The Effect of Oral Niacinamide on Serum Phosphorus Levels in Hemodialysis Patients
Elevated phosphorus levels are a common problem in dialysis patients. However, it is associated with an increase in death and hospitalizations.
- Trial name
- NCT00316472
- Testing
- Niacinamide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine